Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Withdrawn 1

Sponsor Class

NETWORK 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Stomach Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Adenocarcinoma Of Esophagus 1

Interventions

Fluorouracil 9Radiotherapy 8Cisplatin 7Paclitaxel 5Oxaliplatin 5Leucovorin 4Irinotecan 4Cetuximab 3Surgical Procedures, Operative 2Filgrastim 2Docetaxel 2uridine triacetate 1pegylated granulocyte colony-stimulating factor, human 1pegfilgrastim 1dehydroftorafur 1Sorafenib 1Radiation 1Polymerase Chain Reaction 1Platinum 1Granulocyte Colony-Stimulating Factor 1Gemcitabine 1Folfox protocol 1Drug Therapy 1Chemotherapy, Adjuvant 1Capecitabine 1Amplified Fragment Length Polymorphism Analysis 1AMG 337 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NETWORK × Adenocarcinoma Of Esophagus × AMG 337 × Clear all
NCT02344810 2023-05-25

C-Met Inhibitor AMG 337, Oxaliplatin, Leucovorin Calcium, and Fluorouracil in Treating Patients With Advanced Stomach or Esophageal Cancer

Eastern Cooperative Oncology Group

Phase 1/2 Withdrawn
Gastrointestinal

Adenocarcinoma Of Esophagus, Esophageal Neoplasms, Gastrointestinal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡